Experts plan to study the EpiVacCorona vaccine on children in December, said Rinat Maksyutov, director of the Vector Center.
According to him, the research will involve 100 volunteers aged 14 to 17 years.
We plan to launch this study in December this year, he said at the virtual symposium 'COVID-19 Pandemic: Challenge to Modern Science.'
Maksyutov also noted that on November 16, the center received permission to conduct research as part of a transparent, controlled study of the safety of reactogenicity, immunogenicity in people over 60. In total, the specialists intend to attract 150 volunteers.
An open and controlled study of the safety of reactogenicity and immunogenicity in volunteers over 60 years old is 150 volunteers. The permit has already been received on November 16 of this year, said Maksyutov.
Rospotrebnadzor chief Anna Popova earlier expressed hope that the third phase of clinical trials of the EpiVacCorona coronavirus vaccine would begin shortly.
Approved on October 14, EpiVacCorona is being developed at the Novosibirsk center Vector. Its two versions will be available in civil circulation. Both of them do not contain live virus and form immunity through the use of artificially synthesized peptides. Popova and Deputy Prime Minister Tatyana Golikova, who heads the federal operational headquarters for combating COVID-19, were vaccinated with the drug.
NEWS.ru reported earlier that the World Health Organization (WHO) expected a limited supply of coronavirus vaccines to begin in the first half of 2021.